Veru, Inc. (VERU) Climbs 11%, Covid Treatment to Face FDA Panel on Oct. 6
Tweet
Share
E-mailGet Alerts VERU Hot Sheet
Up)Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Veru, Inc. (NASDAQ: VERU) Climbs 11%, Covid Treatment to Face FDA Panel on Oct. 6
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and Singularity and Encourages Investors to Contact the Firm
- Medicinova (MNOV) Completes Enrollment in Phase 2b Trial of MN 166
- Sunrise New Energy (EPOW) to supply $240M in graphite anode to a leading Chinese EV Manufacturer
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
